Business Context and Reporting Period
Company: Galectin Therapeutics Inc. (GALT)
Filing Type: Form 8-K (Current Report)
Date of Report: November 14, 2025
Reporting Period: Nine months ended September 30, 2025
This filing serves as a notification that the company issued a press release on November 14, 2025, announcing its results of operations and financial condition for the nine-month period ended September 30, 2025, along with a business update. The detailed financial data is contained within the attached press release (Exhibit 99.1) and is not explicitly restated in the body of this 8-K form.
Key Financial Metrics
The 8-K filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained in the attached press release (Exhibit 99.1), which is incorporated by reference but not reproduced in the provided text.
Material Changes
The filing does not detail specific material changes versus the prior comparable period. It directs investors to the attached press release for the announcement of results and business updates.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing explicitly states that statements made in the associated press release are forward-looking and involve risks and uncertainties.
- Risk Factors: Future financial performance may differ significantly from management expectations. Investors are directed to the "Risk Factors" section of the Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and subsequent SEC filings for detailed risk information.
- Legal Status: The information in Item 2.02 is furnished, not filed, and will not be incorporated by reference into registration statements unless specifically identified.
Investor Verification Checklist
- Review the attached Press Release (Exhibit 99.1) for specific revenue, net loss, and cash position figures for the nine months ended September 30, 2025.
- Examine the Form 10-K for the year ended December 31, 2024 for comprehensive risk factors and historical context.
- Verify the company's current cash runway and burn rate as disclosed in the press release to assess liquidity.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the business update.